Nucleotide-binding domain of phosphoglycerate kinase 1 reduces tumor growth by suppressing COX-2 expression

Cancer Science

Volumn 101, Issue 11, 2010, Pages 2411-2416

  Ho, Ming Yi ^a   Tang, Shye Jye ^b   Ng, Wailap V ^a   Yang, Winnie ^c   Leu, Shr Jeng J ^a   Lin, Ying Chun ^a   Feng, Chi Kuang ^d   Sung, Jung Sung ^c   Sun, Kuang Hui ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; MESSENGER RNA; PHOSPHOGLYCERATE KINASE; PHOSPHOGLYCERATE KINASE 1; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CARCINOGENICITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; METABOLITE; MOUSE; NONHUMAN; NUCLEOTIDE BINDING DOMAIN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RNA STABILITY; TISSUE LEVEL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; BINDING SITES; BLOTTING, WESTERN; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLOOXYGENASE 2; DINOPROSTONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; NUCLEOTIDES; PHOSPHOGLYCERATE KINASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA STABILITY; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA1; TUMOR BURDEN;

EID: 78049417559     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01691.x     Document Type: Article

References (30)

1. Sun S, Schiller JH, Spinola M, Minna JD. New molecularly targeted therapies for lung cancer. J Clin Invest 2007; 117: 2740-50.
2. Lee JM, Yanagawa J, Peebles KA, Sharma S, Mao JT, Dubinett SM. Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol 2008; 66: 208-17.
3. VandeBerg JL. The phosphoglycerate kinase isozyme system in mammals: biochemical, genetic, developmental, and evolutionary aspects. Isozymes Curr Top Biol Med Res 1985; 12: 133-87.
4. Michelson AM, Blake CC, Evans ST, Orkin SH. Structure of the human phosphoglycerate kinase gene and the intron-mediated evolution and dispersal of the nucleotide-binding domain. Proc Natl Acad Sci USA 1985; 82: 6965-9.
5. Popanda O, Fox G, Thielmann HW. Modulation of DNA polymerases α, δ and ε by lactate dehydrogenase and 3-phosphoglycerate kinase. Biochim Biophys Acta 1998; 1397: 102-17.
6. Ogino T, Iwama M, Kinouchi J, Shibagaki Y, Tsukamoto T, Mizumoto K. Involvement of a cellular glycolytic enzyme, phosphoglycerate kinase, in Sendai virus transcription. J Biol Chem 1999; 274: 35999-6008.
7. Shetty S, Ganachari M, Liu MC, Azghani A, Muniyappa H, Idell S. Regulation of urokinase expression by phosphoglycerate kinase is independent of its catalytic activity. Am J Physiol Lung Cell Mol Physiol 2005; 289: L591-8.
8. Lay AJ, Jiang XM, Kisker O et al. Phosphoglycerate kinase acts in tumor angiogenesis as a disulphide reductase. Nature 2000; 408: 869-73.
9. + colon cancer. Clin Cancer Res 2004; 10: 5828-36.
10. Brown JR, DuBois RN. Cyclooxygenase as a target in lung cancer. Clin Cancer Res 2004; 10: 4266s-9s.
11. Castelao JE, Bart RD III, DiPerna CA, Sievers EM, Bremner RM. Lung cancer and cyclooxygenase-2. Ann Thorac Surg 2003; 76: 1327-35.
12. Hida T, Yatabe Y, Achiwa H et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58: 3761-4.
13. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998; 58: 4997-5001.
14. Põld M, Zhu LX, Sharma S et al. Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer. Cancer Res 2004; 64: 1853-60.
15. Dohadwala M, Batra RK, Luo J et al. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem 2002; 277: 50828-33.
16. Hida T, Kozaki K, Muramatsu H et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000; 6: 2006-11.
17. Sharma S, Yang SC, Zhu L et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res 2005; 65: 5211-20.
18. Sharma S, Zhu L, Yang SC et al. Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses. J Immunol 2005; 175: 813-9.
19. Stolina M, Sharma S, Lin Y et al. Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor response. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000; 164: 361-70.
20. Tang SJ, Ho MY, Cho HC et al. Phosphoglycerate kinase 1-overexpressing lung cancer cells reduce cyclooxygenase 2 expression and promote anti-tumor immunity in vivo. Int J Cancer 2008; 123: 2840-8.
21. Wang J, Wang J, Dai J et al. A glycolytic mechanism regulating an angiogenic switch in prostate cancer. Cancer Res 2007; 67: 149-59.
22. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003; 4: 431-6.
23. Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM. Post-transcriptional control of cyclooxygenase-2 gene expression The role of the 3'-untranslated region. J Biol Chem 2000; 275: 11750-7.
24. Dixon DA, Tolley ND, King PH et al. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest 2001; 108: 1657-65.
25. Sengupta S, Jang BC, Wu MT, Paik JH, Furneaux H, Hla T. The RNA-binding protein HuR regulates the expression of cyclooxygenase-2. J Biol Chem 2003; 278: 25227-33.
26. Kim R, Emi M, Tanabe K, Uchida Y, Toge T. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 2004; 100: 2281-91.
27. Wrzesinski SH, Wan YY, Flavell RA. Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res 2007; 13: 5262-70.
28. Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 2006; 25: 435-57.
29. Young MR, Wright MA, Coogan M, Young ME, Bagash J. Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppres-sion through transforming growth factor beta. Cancer Immunol Immunother 1992; 35: 14-8.
30. Liu Q, Zhang C, Sun A, Zheng Y, Wang L, Cao X. Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I. J Immunol 2009; 182: 6207-16.